JP Morgan Chase
KLRS

JP Morgan Chase’s Kalaris Therapeutics KLRS Stock Holding History

JP Morgan Chase’s Portfolio KLRS Stock Details KLRS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$211 Hold
50
– – ﹤0.01% 7496
2026
Q1 		$265 Hold
50
– – ﹤0.01% 7232
2025
Q4 		$422 Hold
50
– – ﹤0.01% 7095
2025
Q3 		$289 Hold
50
– – ﹤0.01% 7091
2025
Q2 		$134 Sell
50
-245
-83% -$1.11K ﹤0.01% 6811
2025
Q1 		$2.37K Sell
295
-60
-17% -$587 ﹤0.01% 6527
2024
Q4 		$3.43K Buy
355
+260
+274% +$3.93K ﹤0.01% 6573
2024
Q3 		$1.76K Sell
95
-199
-68% -$3.48K ﹤0.01% 6635
2024
Q2 		$4.89K Sell
294
-1,018
-78% -$18K ﹤0.01% 6388
2024
Q1 		$22.8K Sell
1,312
-14,554
-92% -$237K ﹤0.01% 6195
2023
Q4 		$248K Sell
15,866
-30,133
-66% -$1.19M ﹤0.01% 5261
2023
Q3 		$2.27M Sell
45,999
-1,598
-3% -$109K ﹤0.01% 3456
2023
Q2 		$3.72M Buy
47,597
+4,744
+11% +$451K ﹤0.01% 3097
2023
Q1 		$3.88M Buy
42,853
+1,025
+2% +$131K ﹤0.01% 3025
2022
Q4 		$4.94M Buy
41,828
+15,344
+58% +$2.6M ﹤0.01% 2821
2022
Q3 		$4.81M Sell
26,484
-7,247
-21% -$1.13M ﹤0.01% 2779
2022
Q2 		$3.03M Buy
33,731
+518
+2% +$54.3K ﹤0.01% 3215
2022
Q1 		$5.16M Buy
33,213
+7,204
+28% +$1.44M ﹤0.01% 2976
2021
Q4 		$7.74M Sell
26,009
-6,491
-20% -$3.01M ﹤0.01% 2675
2021
Q3 		$18.7M Sell
32,500
-2,484
-7% -$1.15M ﹤0.01% 1825
2021
Q2 		$15.9M Buy
34,984
+13,310
+61% +$6.87M ﹤0.01% 2041
2021
Q1 		$11.7M Buy
21,674
+21,323
+6,075% +$17.9M ﹤0.01% 2221
2020
Q4 		$310K Buy
351
+60
+21% +$46.2K ﹤0.01% 4637
2020
Q3 		$180K Buy
+291
New +$199K ﹤0.01% 4414

Other funds holding KLRS

SB
Samsara BioCapital Palo Alto, California $1.22B AUM 242.83% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
Alyeska Investment Group
Alyeska Investment Group Chicago, Illinois $38.9B AUM 28.51% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $4.94B AUM 244.43% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
IC
Ikarian Capital Dallas, Texas $928M AUM 596.14% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

JP Morgan Chase's KLRS Position: Q2 2026 in Review

JP Morgan Chase held its Kalaris Therapeutics (KLRS) position steady in Q2 2026 at 50 shares worth $211. The position accounts for ﹤0.01% of the portfolio, ranked #7496.

JP Morgan Chase first reported a position in KLRS in Q3 2020 and has held it in 24 quarters since. The position peaked at $18.7M in Q3 2021. 57 funds tracked by Wall St. Rank hold KLRS as of Q2 2026.

  • JP Morgan Chase held 50 shares of Kalaris Therapeutics worth $211 as of Q2 2026.
  • JP Morgan Chase left its Kalaris Therapeutics share count unchanged in Q2 2026.
  • Kalaris Therapeutics made up ﹤0.01% of JP Morgan Chase's portfolio in Q2 2026, its #7496 holding.
  • JP Morgan Chase first reported a position in Kalaris Therapeutics in Q3 2020 and has held it in 24 quarters since.
  • JP Morgan Chase's Kalaris Therapeutics position peaked at $18.7M in Q3 2021.
  • 57 funds tracked by Wall St. Rank held Kalaris Therapeutics as of Q2 2026.

Based on JP Morgan Chase's 13F filing for Q2 2026, filed 12 Aug 2026.